Plasma cellsare the terminally differentiated nondividing products of the Bcell lineage. They constitutively secrete antibodies at high rate and persist in survival niches of the bone marrow thus maintainingserum antibody levelsconstant [58]. At the peak of a secondary response (day 7 after boosting...
Stem cell transplantationMultiple myelomaOverall survivalPlasma cell leukemia (PCL) is an aggressive rare leukemic variant of multiple myeloma (MM). We aim to present 4years data on clinical profile and treatment outcomes of Primary PCL (PPCL) patients treated at tertiary care cancer centre from ...
Plasma cell leukemia Nonsecretory myeloma Solitary plasmacytoma Primary amyloidosis Heavy chain disease POEMS Adapted fromKyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am 2007;21:1093. ...
we used the Benjamini–Hochberg procedure58and controlled the false discovery rate (FDR) < 5%. All analyses were performed in R version 4.1.0. The main R packages used were ‘missRanger 2.1.5’ for random forest imputation, ‘survival 3.4-0’ for Cox regression, ‘fgsea 1.23.2’ for...
Plasma cell leukemia: Typically aggressive with short survival < 1 year > 2 x 109/L or 20% of the leukocyte count on differential are monoclonal plasma cells Primary plasma cell leukemia (0.6% of myeloma) or develop as a late stage transformation (secondary) (Curr Oncol Rep 2019;21:8) ...
Primary plasma cell leukemia (pPCL) is a rare and aggressive form of multiple myeloma (MM) that is characterized by the presence of ≥20% circulating plasma cells. Overall survival remains poor despite advances of anti-MM therapy. The disease biology as well as molecular mechanisms that distingui...
Leukemia (leukapheresis) (for acute debulking only) including mantle cell lymphoma (mantle cell leukemia) if white blood cells count is greater than 100,000/µL; or Myasthenia gravis, in persons with any of the following: Acute, short-term benefit is critical because of a sudden worsening of...
Takatsuki syndrome) Not reported in the feline literature Plasma cell leukemia (Myeloma with leukemic overspill) Variable criteria used historically; typical example—peripheral blood plasma cells >20% or >2 × 109 cells/L 49 Low proliferative clonal plasma cell disorders as protein deposition diseases...
Two-year progression-free survival (PFS) was 40% and 2-year OS 55%, with the best long-term results achieved in patients who received stem cell transplantation (SCT) after bortezomib induction.71 In another retrospective analysis, Musto et al showed that response rate to bortezomib or ...
Plasma Cell Leukemia Plasma cell leukemia (PCL) is a rare and aggressive MRD characterized by the presence of circulating plasma cells (see Table 55-2). Note that nonneoplastic conditions, such as severe sepsis, can occasionally result in transient elevations of circulating plasma cells.147 The...